Most recently, a collagen-binding glycoprotein, Hsp47 (colligin), has been shown to be a potential marker for tumor malignancy (4,5). However, the mechanism for the malignancy suppresser effects of Hsp47 have to date not been investigated. The hypothesis upon which this proposal is based is that Hsp47 is a 47-kD collagen-binding endoplasmic reticulum [ER] glycoprotein that is limited to cells which can produce collagens. However, Hsp47 can elude its COOH-terminus retention mechanism and be expressed on the surface of squamous carcinoma cells [SCCs]. The presence of Hsp47 on the cell surface of SCCs inhibits cell motility and thereby impedes SCC cell invasion into extracellular matrices. The mechanism for inhibiting tumor cell invasion resides either in: a) Hsp47's properties as an inhibitory serpin protein; b) the cell membrane complexes of Hsp47/TM4Sfproteins/? that affect membrane signaling; or c) as an autocrine inhibitor of tumor cell motility. This hypothesis will be tested through the accomplishment of four specific aims. These are as follows: 1. Verify that Hsp47, which is manifest on the cell surface of human SCCs, correlates with the ability of SCCs to invade extracellular matrices using in vitro assays and an in vivo athymic nude mouse model. 2. Determine whether Hsp47 expressed on the surface of human SCCs and/or presence within the incubation medium impedes SCC invasion by acting as an inhibitory serpin protein. 3. Determine other mechanisms by which Hsp47 may exert an effect on tumor cell motility and invasion.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Research Project (R01)
Project #
5R01DE012606-02
Application #
6150537
Study Section
Oral Biology and Medicine Subcommittee 1 (OBM)
Program Officer
Sandberg, Ann
Project Start
1999-02-01
Project End
2003-01-31
Budget Start
2000-02-01
Budget End
2001-01-31
Support Year
2
Fiscal Year
2000
Total Cost
$250,994
Indirect Cost
Name
University of Maryland Baltimore
Department
Dentistry
Type
Schools of Dentistry
DUNS #
003255213
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Nikitakis, Nikolaos G; Scheper, Mark A; Papanikolaou, Vasileios S et al. (2009) The oncogenic effects of constitutive Stat3 signaling in salivary gland cancer cells are mediated by survivin and modulated by the NSAID sulindac. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 107:826-36
Nikitakis, Nikolaos G; Scheper, Mark A; Papanikolaou, Vasileios S et al. (2009) Immunohistochemical expression of the oncogenic molecules active Stat3 and survivin in benign and malignant salivary gland tumors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 107:837-43
Scheper, M A; Nikitakis, N G; Sauk, J J (2007) Survivin is a downstream target and effector of sulindac-sensitive oncogenic Stat3 signalling in head and neck cancer. Int J Oral Maxillofac Surg 36:632-9
Scheper, Mark A; Nikitakis, Nikolaos G; Chaisuparat, Risa et al. (2007) Sulindac induces apoptosis and inhibits tumor growth in vivo in head and neck squamous cell carcinoma. Neoplasia 9:192-9
Hebert, Carla; Norris, Kathleen; Scheper, Mark A et al. (2007) High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer 6:5
Hebert, Carla; Norris, Kathleen; Parashar, Pallavi et al. (2006) Hypoxia-inducible factor-1alpha polymorphisms and TSC1/2 mutations are complementary in head and neck cancers. Mol Cancer 5:3
Scheper, Mark A; Sauk, John J; Nikitakis, Nikolaos G (2006) COX-independent antineoplastic effects of sulindac in oral cancer are mediated by survivin down-regulation. Anticancer Res 26:4103-13
Nan, Anjan; Ghandehari, Hamidreza; Hebert, Carla et al. (2005) Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck. J Drug Target 13:189-97
Hebert, Carla; Siavash, Hessam; Norris, Kathleen et al. (2005) Endostatin inhibits nitric oxide and diminishes VEGF and collagen XVIII in squamous carcinoma cells. Int J Cancer 114:195-201
Sauk, John J; Nikitakis, Nikolaos; Siavash, Hessam (2005) Hsp47 a novel collagen binding serpin chaperone, autoantigen and therapeutic target. Front Biosci 10:107-18

Showing the most recent 10 out of 24 publications